U.S. Markets closed

Cogent Biosciences, Inc. (COGT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.31+0.11 (+1.34%)
At close: 4:00PM EDT

Cogent Biosciences, Inc.

200 Cambridge Park Drive
Suite 2500
Cambridge, MA 02140
United States
617 945 5576
http://www.cogentbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees15

Key Executives

NameTitlePayExercisedYear Born
Mr. Andrew R. Robbins M.B.A.Pres, CEO & DirectorN/AN/A1976
Mr. John L. Green C.A., CPACFO & Principal Accounting OfficerN/AN/A1980
Mr. Brad BarnettChief Technology OfficerN/AN/AN/A
Dr. John Robinson Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Erin SchellhammerChief People OfficerN/AN/AN/A
Dr. Jessica Sachs M.D.Chief Medical OfficerN/AN/A1975
Ms. Sara SaltzmanSr. VP of Regulatory AffairsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Cogent Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.